UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 337

Sortiert nach

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

Allergy (Copenhagen), 2021-06, Vol.76 (6), p.1789-1799

2021

Volltextzugriff (PDF)

Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-06, Vol.9 (6), p.2305-2314.e4

2021

Volltextzugriff (PDF)

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Clinical and translational allergy, 2021-06, Vol.11 (4), p.e12035-n/a

2021

Volltextzugriff (PDF)

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Journal of allergy and clinical immunology, 2021-07, Vol.148 (1), p.164-172.e9

2021

Volltextzugriff (PDF)

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2011-05, Vol.17 (10), p.3420-3430

2011

Volltextzugriff (PDF)

Single-Dose Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Protease Inhibitor

Antimicrobial Agents and Chemotherapy, 2006-06, Vol.50 (6), p.2201-2206

2006

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, following Repeat Administration with and without Ritonavir in Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy, 2007-04, Vol.51 (4), p.1202-1208

2007

Volltextzugriff (PDF)

A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma

Journal of immunotherapy (1997), 2013-07, Vol.36 (6), p.331

2013

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

Journal of clinical pharmacology, 2010-06, Vol.50 (6), p.623-635

2010

Volltextzugriff (PDF)

Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study

Journal of clinical pharmacology, 2010-06, Vol.50 (6), p.636-646

2010

Volltextzugriff (PDF)

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist

Investigational new drugs, 2012-04, Vol.30 (2), p.662-671

2012

Volltextzugriff (PDF)

Sample Size Calculations for Crossover Thorough QT Studies: Satisfaction of Regulatory Threshold and Assay Sensitivity

Journal of biopharmaceutical statistics, 2010-05, Vol.20 (3), p.563-579

2010

Volltextzugriff (PDF)

Crohn's disease: does race matter?

The American journal of gastroenterology, 2000-02, Vol.95 (2), p.479-483

2000

Volltextzugriff (PDF)

Effect of Casopitant, a Novel NK-1 Receptor Antagonist, on the Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin

Journal of clinical pharmacology, 2010-05, Vol.50 (5), p.566-575

2010

Volltextzugriff (PDF)

Intestinal effects of sulfate in drinking water on normal human subjects

Digestive diseases and sciences, 1997-05, Vol.42 (5), p.1055-1061

1997

Volltextzugriff (PDF)

The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening

The American journal of gastroenterology, 2000-11, Vol.95 (11), p.3259-3265

2000

Volltextzugriff (PDF)

The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening

The American journal of gastroenterology, 2000, Vol.95 (11), p.3259-3265

2000

Volltextzugriff (PDF)

Next Generation Pharmaceutical Impactor (A new Impactor for Pharmaceutical inhaler testing). Part II: Archival calibration

Journal of aerosol medicine, 2003-09, Vol.16 (3), p.301-324

2003

Volltextzugriff (PDF)

Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas

Gastroenterology (New York, N.Y. 1943), 1998-03, Vol.114 (3), p.441-447

1998

Volltextzugriff (PDF)

Micronutrients and the Risk of Colorectal Adenomas

American journal of epidemiology, 1996-12, Vol.144 (11), p.1005-1014

1996

Volltextzugriff (PDF)

Abstract C132: Effect of hepatic or renal impairment on the pharmacokinetics of casopitant

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C132-C132

2009

Volltextzugriff (PDF)

Plasma selenium levels and the risk of colorectal adenomas

Nutrition and cancer, 1997, Vol.28 (2), p.125-129

1997

Volltextzugriff (PDF)

Crohn’s disease: does race matter?

The American journal of gastroenterology, 2000, Vol.95 (2), p.479-483

2000

Volltextzugriff (PDF)

Rectal mucosal proliferation, dietary factors, and the risk of colorectal adenomas

Cancer epidemiology, biomarkers & prevention, 1998-11, Vol.7 (11), p.993-999

1998

Volltextzugriff (PDF)

An application of a multi-stage strategy involving confidence intervals to evaluate whether a response rate is favourable or not

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2004-01, Vol.3 (1), p.25-37

2004

Volltextzugriff (PDF)

1 – 25 von 337

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(317)
Mit Volltextzugriff
(273)

Publikationsform

Sprache

Englisch
(337)
Japanisch
(50)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

Single-Dose Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Protease Inhibitor

Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, following Repeat Administration with and without Ritonavir in Healthy Adult Subjects

A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma

Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist

Sample Size Calculations for Crossover Thorough QT Studies: Satisfaction of Regulatory Threshold and Assay Sensitivity

Crohn's disease: does race matter?

Effect of Casopitant, a Novel NK-1 Receptor Antagonist, on the Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin

Intestinal effects of sulfate in drinking water on normal human subjects

The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening

The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening

Next Generation Pharmaceutical Impactor (A new Impactor for Pharmaceutical inhaler testing). Part II: Archival calibration

Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas

Micronutrients and the Risk of Colorectal Adenomas

Abstract C132: Effect of hepatic or renal impairment on the pharmacokinetics of casopitant

Plasma selenium levels and the risk of colorectal adenomas

Crohn’s disease: does race matter?

Rectal mucosal proliferation, dietary factors, and the risk of colorectal adenomas

An application of a multi-stage strategy involving confidence intervals to evaluate whether a response rate is favourable or not

Suchergebnisse filtern